FDA Approves Velsipity for Moderate-to-Severe Ulcerative Colitis in Adults
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Oct. 17, 2023 -- The U.S. Food and Drug Administration approved Velsipity (etrasimod) for adults with moderately to severely active ulcerative colitis (UC).
The approval was based on results from the ELEVATE UC phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) that included UC patients who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase inhibitor therapy. In ELEVATE UC 52, 27.0 percent of patients receiving Velsipity achieved clinical remission versus 7.0 percent of patients receiving placebo at week 12, and at week 52, clinical remission was achieved by 32.0 and 7.0 percent, respectively. In ELEVATE UC 12, 26.0 percent of patients receiving Velsipity achieved clinical remission versus 15.0 percent of patients receiving placebo. At week 12, all key secondary efficacy end points were met, including endoscopic improvement and mucosal healing.
The selective sphingosine-1-phosphate receptor modulator was approved at a 2-mg recommended dose. The safety of Velsipity was consistent with previous studies, with the most common adverse reactions being headache, elevated liver tests, and dizziness (incidence ≥5 percent).
"Velsipity provides adults living with moderately-to-severely active UC the opportunity to achieve steroid-free remission with an oral, once-daily pill that has a favorable benefit-risk profile," Angela Hwang, Pfizer chief commercial officer and president of global biopharmaceuticals business, said in a statement.
Approval of Velsipity was granted to Pfizer.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Baby's Diet Could Cut Lifetime Odds for Crohn's, Colitis
WEDNESDAY, Jan. 31, 2024 -- Toddlers are famously picky eaters, but parents may be doing their young child's future gut a huge favor if they insist on a healthy diet. New...
Crohn's, Colitis Vary by Race, Gender
FRIDAY, Jan. 5, 2023 -- Crohn's disease and ulcerative colitis show different patterns of incidence by race, gender and even place of birth, a new U.S. study finds. The two...
Subtle Changes Could Predict Inflammatory Bowel Disease Years Before Symptoms Hit
MONDAY, Nov. 13, 2023 (Healthday News) -- Inflammatory bowel disease starts to develop years before patients come down with symptoms, a new study suggests. Gut changes can be...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
